New shot tested for Tough-to-Treat arthritis

NCT ID NCT07230353

Summary

This early-stage study is testing the safety and side effects of a new drug called plamotamab in adults with moderate to severe rheumatoid arthritis. About 47 participants who haven't responded well to standard arthritis medications will receive injections of the drug at different dose levels. The main goal is to see how well people tolerate the treatment and to understand how the drug behaves in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Arensia Research Clinic

    NOT_YET_RECRUITING

    Tbilisi, Georgia

  • Arensia Research Clinic

    RECRUITING

    Chisinau, Moldova

  • Xencor Investigative Site

    NOT_YET_RECRUITING

    Tbilisi, Georgia

  • Xencor Investigative Site

    NOT_YET_RECRUITING

    Auckland, New Zealand

Conditions

Explore the condition pages connected to this study.